Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
NCT00045864 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2006-02-06
Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
- DRUG
-
Recombinant Human Interleukin-2 and Rituximab
Sponsors & Collaborators
-
Chiron Corporation
lead INDUSTRY
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00004260 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00026182 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
NCT00100737 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
NCT00517049 ·Status: COMPLETED ·Phase: PHASE2
-
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
NCT00250861 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
NCT00003849 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
NCT01980654 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01829568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
NCT00003356 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00244985 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00005959 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
NCT00210340 ·Status: WITHDRAWN ·Phase: PHASE1
-
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
NCT00248534 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
NCT00500058 ·Status: COMPLETED ·Phase: PHASE1
-
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
NCT00062114 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
NCT00460109 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00040950 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
NCT00994643 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00143871 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
NCT01649856 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
NCT00072449 ·Status: TERMINATED ·Phase: PHASE2